trending Market Intelligence /marketintelligence/en/news-insights/trending/_xn_9m0prdfbvlxelb3bfa2 content esgSubNav
In This List

Seattle Genetics appoints chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Seattle Genetics appoints chief medical officer

Seattle Genetics Inc. said May 17 that it named Roger Dansey chief medical officer.

Dansey was most recently senior vice president at Merck & Co. Inc., where he was therapeutic area head for late-stage oncology. Before joining Merck, he worked at Gilead Sciences Inc. as vice president of oncology clinical research.

Dansey replaces Jonathan Drachman, who will continue to work with Seattle Genetics as a strategic adviser for innovation.

Bothell, Wash.-based Seattle Genetics is a biotechnology company that develops and sells targeted cancer therapies.